# EDGAR Filing Document

**Accession Number:** 0001699737
**File Stem:** 0001699737-25-000010
**Filing Date:** 2025-10
**Character Count:** 17916
**Document Hash:** ba1f3c3897cc0af78b1d87d2d4fe3bf9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001699737-25-000010.hdr.sgml**: 20251021

**ACCESSION NUMBER**: 0001699737-25-000010

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251021

**DATE AS OF CHANGE**: 20251021

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inventiva S.A.
- **CENTRAL INDEX KEY:** 0001756594
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91576
- **FILM NUMBER:** 251407122

**BUSINESS ADDRESS:**
- **STREET 1:** 50 RUE DE DIJON
- **CITY:** DAIX
- **STATE:** I0
- **ZIP:** 21121
- **BUSINESS PHONE:** 33380447500

**MAIL ADDRESS:**
- **STREET 1:** 50 RUE DE DIJON
- **CITY:** DAIX
- **STATE:** I0
- **ZIP:** 21121
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Samsara BioCapital, L.P.
- **CENTRAL INDEX KEY:** 0001699737

**ORGANIZATION NAME:**
- **EIN:** 813958301
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 628 MIDDLEFIELD ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** (650) 285-4270

**MAIL ADDRESS:**
- **STREET 1:** 628 MIDDLEFIELD ROAD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301

## Exhibit 99.1

EXHIBIT 99.1

JOINT FILING AGREEMENT

We, the undersigned, hereby express our agreement that the Schedule 13D (or any amendments thereto) relating to the Ordinary Shares of Inventiva S.A. is filed on behalf of each of us.

Dated: October 17, 2025

**Samsara BioCapital, L.P.**

By:

Samsara BioCapital GP, LLC

its

General Partner

By:

<u>/s/ Srinivas Akkaraju</u>

Name: Srinivas Akkaraju

Title: Managing Member

**Samsara BioCapital GP, LLC**

By:

<u>/s/ Srinivas Akkaraju</u>

Name: Srinivas Akkaraju

Title: Managing Member

<u>/s/ Srinivas Akkaraju</u> 

Srinivas Akkaraju

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Inventiva S.A.**

*(Name of Issuer)*

**Ordinary shares, nominal value (euro) 0.01 per share**

*(Title of Class of Securities)*

**46124U107**

*(CUSIP Number)*

**Abrar Hussain**<br>Samsara BioCapital GP, LLC<br>628 Middlefield Road<br>Palo Alto CA 94301<br>(650) 285-4270

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**05/07/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **46124U107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Samsara BioCapital, L.P.** | Name of reporting person<br>**Samsara BioCapital, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**8161942.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**8161942.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**8161942.00** | Aggregate amount beneficially owned by each reporting person<br>**8161942.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.9%** | Percent of class represented by amount in Row (11)<br>**5.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Note:  There is no CUSIP number assigned to the Ordinary Shares. The CUSIP Number 46124U107 has been assigned to the American Depositary Shares ("ADS") of the Issuer, which are quoted on the Nasdaq Global Market under the symbol "IVA". Each ADS represents 1 Ordinary Share.

| **CUSIP No.** | **46124U107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Samsara BioCapital GP, LLC** | Name of reporting person<br>**Samsara BioCapital GP, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**8161942.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**8161942.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**8161942.00** | Aggregate amount beneficially owned by each reporting person<br>**8161942.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.9%** | Percent of class represented by amount in Row (11)<br>**5.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **46124U107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Srinivas Akkaraju** | Name of reporting person<br>**Srinivas Akkaraju** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**8161942.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**8161942.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**8161942.00** | Aggregate amount beneficially owned by each reporting person<br>**8161942.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.9%** | Percent of class represented by amount in Row (11)<br>**5.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary shares, nominal value (euro) 0.01 per share

**(b) Name of Issuer:**
Inventiva S.A.

**(c) Address of Issuer's Principal Executive Offices:**
50 rue de Dijon, Daix, I0, 21121

**Item 4. Purpose of Transaction**

The Reporting Persons purchased the aforementioned securities for investment purposes with the aim of increasing the value of their investments and the Issuer. Subject to applicable legal requirements, one or more of the Reporting Persons may purchase additional securities of the Issuer from time to time in open market or private transactions, depending on its evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Persons' ownership of the Issuer's securities, other opportunities available to the Reporting Persons, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above, the Reporting Persons may dispose of all or a portion of their securities of the Issuer at any time (including by means of programs adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Act")). Each of the Reporting Persons reserve the right to increase or decrease its holdings on such terms and at such times as each may decide.

Except as set forth in this Item 4 and Item 6 below, none of the Reporting Persons have a present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Act. However, each of the Reporting Persons reserves the right to propose or participate in future transactions which may result in one or more of such actions, including but not limited to, an extraordinary corporate transaction, such as a merger, reorganization or liquidation, sale of a material amount of assets of the Issuer or its subsidiaries, or other transactions which might have the effect of causing the Ordinary Shares to become eligible for termination of registration under Section 12(g) of the Act. The Reporting Persons also retain the right to change their investment intent at any time, to acquire additional shares of the Ordinary Shares or other securities of the Issuer from time to time, or to sell or otherwise dispose of all or part of the Ordinary Shares beneficially owned by them (or any Ordinary Shares into which such securities are converted) in any manner permitted by law. The Reporting Persons may engage from time to time in ordinary course transactions with financial institutions with respect to the securities described herein.

In connection with the Transaction, the Issuer appointed Dr. Akkaraju, the Managing Member of Samsara GP, to serve as a member of the board of directors of the Issuer on December 11, 2024 following approval of the Issuer's shareholders. As a director of the Issuer, Dr. Akkaraju may have influence over the corporate activities of the Issuer, including activities which may relate to the transactions described in clauses (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D set forth the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon 139,151,274 Ordinary Shares outstanding as of June 30, 2025, as reported in Exhibit 99.2 attached to the Company's Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission (the "SEC") on September 29, 2025.

The Reporting Persons' ownership of the Issuer's securities consists of (i) 8,161,942 Ordinary Shares; (ii) 4,645,925 Pre-funded Warrants; and (iii) 6,637,037 Performance Warrants (exercisable for up to 5,973,333 Ordinary Shares), each directly held by Samsara LP. Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is the managing member of Samsara GP. Each of Samsara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP. The Pre-funded Warrants contain a provision (the "Beneficial Ownership Blockers") which precludes exercise of the Pre-funded Warrants to the extent that, following exercise, Samsara LP, together with its affiliates and other attribution parties, would own more than 4.99% of the outstanding Ordinary Shares. The exercise of the Performance Warrants is subject to the Issuer's release of topline data announcing that any key primary endpoint or key secondary endpoint of its NATiV3, with any dosage regime tested in the trial, have been met no later than June 15, 2027 (the "Triggering Milestone"). By virtue of the Beneficial Ownership Blockers and the Triggering Milestone, the Pre-funded Warrants and Performance Warrants are currently not exercisable and the Ordinary Shares issuable upon exercise of such warrants are not considered beneficially owned as of the date of this filing.

**(b)**
Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D set forth the number of Ordinary Shares as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.

**(c)**
Except as set forth below and elsewhere in this report, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer since the date of the Initial Closing:

On October 3, 2025, Samsara LP sold 42,774 Ordinary Shares in open market transactions at prices ranging from $5.24 to $5.40 per share (a weighted-average price of $5.34 per share).

On October 6, 2025, Samsara LP sold 40,233 Ordinary Shares in open market transactions at prices ranging from $5.03 to $5.09 per share (a weighted-average price of $5.06 per share).

On October 7, 2025, Samsara LP sold 24,572 Ordinary Shares in open market transactions at prices ranging from $4.76 to $5.15 per share (a weighted-average price of $4.88 per share).

On October 8, 2025, Samsara LP sold 19,140 Ordinary Shares in open market transactions at prices ranging from $4.52 to $4.71 per share (a weighted-average price of $4.58 per share).

On October 9, 2025, Samsara LP sold 221,166 Ordinary Shares in open market transactions at prices ranging from $4.01 to $4.39 per share (a weighted-average price of $4.21 per share).

On October 10, 2025, Samsara LP sold 118,321 Ordinary Shares in open market transactions at prices ranging from $3.93 to $4.12 per share (a weighted-average price of $4.07 per share).

The foregoing Ordinary Shares were held by Samsara LP for the exclusive benefit of limited partners who had redeemed their respective interests in Samsara LP and in which neither Samsara GP nor Dr. Akkaraju had any economic interest.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information with respect to the Pre-funded Warrants and the Performance Warrants set forth in Item 3 and Item 5 above is incorporated herein by reference.

Equity Awards

Dr. Akkaraju is a member of the Board of Directors of the Issuer. From time to time, Dr. Akkaraju may receive stock options or other awards of equity-based compensation pursuant to the Issuer's compensation arrangements for non-employee directors.

The description of the Pre-funded Warrants set forth herein is qualified in its entirety by reference to the full text of the form of Pre-funded Warrant filed as Exhibit 99.2 and incorporated by reference herein.

The description of the Performance Warrants set forth herein is qualified in its entirety by reference to the full text of the form of Performance Warrant filed as Exhibit 99.3 and incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Samsara BioCapital, L.P.

**Signature:** /s/ Srinivas Akkaraju

**Name/Title:** By Samsara BioCapital GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member

**Date:** 10/21/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Samsara BioCapital GP, LLC

**Signature:** /s/ Srinivas Akkaraju

**Name/Title:** By Srinivas Akkaraju, Managing Member

**Date:** 10/21/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Srinivas Akkaraju

**Signature:** /s/ Srinivas Akkaraju

**Name/Title:** Srinivas Akkaraju

**Date:** 10/21/2025